Elevance Health (NYSE:ELV) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Elevance Health, Inc. (NYSE:ELV). In a filing disclosed on June 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Elevance Health stock on May 30th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

Elevance Health Stock Performance

ELV traded up $5.19 during trading on Tuesday, hitting $281.64. The stock had a trading volume of 3,503,806 shares, compared to its average volume of 1,687,259. The company has a 50 day moving average price of $371.52 and a 200-day moving average price of $396.02. The firm has a market cap of $63.63 billion, a price-to-earnings ratio of 11.98, a P/E/G ratio of 0.81 and a beta of 0.60. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Elevance Health, Inc. has a one year low of $274.40 and a one year high of $567.26.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The company reported $8.84 earnings per share for the quarter, missing the consensus estimate of $9.30 by ($0.46). Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The company had revenue of $49.42 billion during the quarter, compared to analyst estimates of $48.26 billion. During the same period in the previous year, the company posted $10.12 EPS. The company's quarterly revenue was up 14.3% on a year-over-year basis. As a group, research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Wednesday, September 10th will be paid a dividend of $1.71 per share. The ex-dividend date of this dividend is Wednesday, September 10th. This represents a $6.84 annualized dividend and a dividend yield of 2.43%. Elevance Health's dividend payout ratio is currently 29.11%.

Insider Activity at Elevance Health

In other Elevance Health news, CEO Gail Boudreaux bought 8,500 shares of the business's stock in a transaction on Friday, July 18th. The stock was bought at an average price of $286.94 per share, with a total value of $2,438,990.00. Following the completion of the purchase, the chief executive officer directly owned 151,020 shares in the company, valued at $43,333,678.80. The trade was a 5.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Kaye sold 4,588 shares of the business's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total value of $1,949,074.16. Following the transaction, the chief financial officer directly owned 18,977 shares of the company's stock, valued at $8,061,809.14. The trade was a 19.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen cut Elevance Health from a "buy" rating to a "hold" rating in a research report on Friday. Wells Fargo & Company decreased their price target on Elevance Health from $478.00 to $400.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. Robert W. Baird restated a "neutral" rating and set a $529.00 price objective (down previously from $625.00) on shares of Elevance Health in a research report on Tuesday, April 15th. JPMorgan Chase & Co. dropped their price target on Elevance Health from $472.00 to $384.00 and set an "overweight" rating for the company in a research report on Tuesday. Finally, Barclays lowered their price target on Elevance Health from $434.00 to $358.00 and set an "overweight" rating for the company in a report on Friday. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $432.69.

Institutional Trading of Elevance Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Accredited Wealth Management LLC bought a new position in shares of Elevance Health in the 4th quarter worth $25,000. Flagship Wealth Advisors LLC purchased a new position in Elevance Health during the fourth quarter worth approximately $26,000. Private Wealth Management Group LLC boosted its position in Elevance Health by 152.0% during the first quarter. Private Wealth Management Group LLC now owns 63 shares of the company's stock worth $27,000 after purchasing an additional 38 shares in the last quarter. OFI Invest Asset Management purchased a new position in shares of Elevance Health in the fourth quarter valued at approximately $29,000. Finally, WealthTrak Capital Management LLC acquired a new stake in shares of Elevance Health in the fourth quarter valued at approximately $29,000. Institutional investors own 89.24% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.